Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 14/20 | 0.35 |
| ▸ | CASP6 | P55212 | 12/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 12/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268871 | 1.00 | CYP2D6 (0.36) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL627300 | 0.92 | CYP2D6 (0.37) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL627299 | 0.92 | CYP2D6 (0.37) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL4421626 | 0.92 | CYP2D6 (0.37) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL12716141 | 0.85 | CYP2D6 (0.35) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL20827204 | 0.85 | MAPT (0.36) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL7357612 | 0.82 | MAPK1 (0.40) | ALDH1A1CASP3CASP6CASP8 | |
| SCHEMBL4420429 | 0.82 | MAPK1 (0.40) | ALDH1A1CASP3CASP6CASP8 | |
| SCHEMBL79263 | 0.82 | MAPT (0.35) | CYP2D6KDM4EALDH1A1MAPTHTT | |
| SCHEMBL473148 | 0.82 | MAPT (0.35) | CYP2D6KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| EP-3572402-B1 | LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| WO-2021073643-A1 | DRUG FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | 正大天晴药业集团股份有限公司 | 2021-04-22 | — | — | WO | disclosed |
| EP-3142649-B1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITOR EMRICASAN | CONATUS PHARMACEUTICALS INC (US) | 2019-07-24 | — | — | EP | disclosed |
| EP-3444011-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH EMRICASAN | Conatus Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC (US) | 2019-01-24 | — | — | US | disclosed |
| EP-3397251-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | Conatus Pharmaceuticals, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017117478-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CONATUS PHARMACEUTICALS INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CONATUS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-7053056-B2 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1351975-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-6544951-B2 | Antiinflammatory agents; autoimmune diseases, nervous system degradation | IDUN PHARMACEUTICALS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2002057298-A2 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1091930-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| US-6197750-B1 | ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS | IDUN PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| WO-2000001666-A1 | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022043-A1 | METHODS OF USING CASPASE INHIBITORS IN TREATMENT OF LIVER DISEASE | CASP1, CASP5, CASP2 | CYP2D6 2779/4885KDM4E 2713/4885ALDH1A1 1171/4885 |
| US-20020028774-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | CYP2D6 4245/4885KDM4E 2938/4885ALDH1A1 4170/4885 |
| US-20170100448-A1 | TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE WITH CASPASE INHIBITORS | CASP1, CASP2, CASP5 | CYP2D6 4320/4885KDM4E 3222/4885ALDH1A1 3238/4885 |
| US-20050020504-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CASP3, DPP3, IAPP | CYP2D6 4245/4885KDM4E 2938/4885ALDH1A1 4170/4885 |
| US-11434212-B2 | Bicyclic compound as a caspase inhibitor | CASP1, CASP14, CASP2 | CYP2D6 2330/4885KDM4E 2705/4885ALDH1A1 3348/4885 |
| US-20020042376-A1 | C-terminal modified oxamyl dipeptides as inhibitors of the ICE-ced-3 family of cysteine proteases | CASP3, IAPP, DPP3 | CYP2D6 4271/4885KDM4E 2999/4885ALDH1A1 4157/4885 |
| US-20210332019-A1 | Bicyclic Compound as a Caspase Inhibitor | CASP1, CASP14, CASP2 | CYP2D6 2330/4885KDM4E 2705/4885ALDH1A1 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.